Daniel Campos Jesus

Daniel Campos Jesus

Auto-generated profile, based on publicly available information

Daniel Campos Jesus

Center for Life Sciences Courses, Pontifical Catholic University of Campinas, Campinas, Brazil

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2023 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
JBJoaquim Barreto
Joaquim Barreto
CBCynthia Borges
Cynthia Borges
TRTaís Betoni Rodrigues
Taís Betoni Rodrigues
DJDaniel C. Jesus
Daniel C. Jesus
ACAlessandra M. Campos-Staffico
Alessandra M. Campos-Staffico
ASAndrei C Sposito
Andrei C Sposito
Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors attenuate incident cardiovascular outcomes, irrespective of baseline GFR, in conservatively managed CKD. As this condition inexorably progresses to demanding KRT, drug withdrawal is supported by the current lack of evidence of safety of SGLT2 inhibitors in dialysis. Methods: This study was a prospective, single-center, open-label trial (ClinicalTrials.gov identifier: NCT05343078) aimed at assessing the pharmacokinetic properties and safety of dapagliflozin in patients with kidney failure on regular dialysis regimens compared with those with type 2 diabetes and age- and sex-matched controls with normal kidney function. Peripheral blood samples were collected from both groups every 30 minutes for 4 hours and again after 48 hours after ingestion of dapagliflozin 10 mg, which occurred immediately before dialysis session initiation in the kidney failure group. This protocol occurred in drug-naïve patients and again after six daily doses of dapagliflozin to assess whether the drug had accumulated. The plasma and dialysate levels of dapagliflozin at each time point were determined by liquid chromatography and used to calculate pharmacokinetics parameters (peak concentration [Cmax] and area under the plasma concentration-versus-time curve) for each participant. Results: Dapagliflozin Cmax was 117 and 97.6 ng/ml in the kidney failure and control groups, respectively, whereas the corresponding accumulation ratios were 26.7% and 9.5%. No serious adverse events were reported for either group. Dapagliflozin recovered from dialysate corresponded to 0.10% of the administered dose. Conclusions: In patients with kidney failure on dialysis, dapagliflozin was well tolerated, was slightly dialyzable, and had nonaccumulating pharmacokinetic properties. Clinical Trial registry name and registration number: Pharmacokinetics and Dialyzability of Dapagliflozin in Dialysis Patients (DARE-ESKD 1), NCT05343078

23 April 2025 in International Journal of Obesity
Verified
Journal Article
Closed access
PDF file
LSLuis Gustavo Sedenho-Prado
Luis Gustavo Sedenho-Prado
LYLouise Buonalumi Tacito Yugar
Louise Buonalumi Tacito Yugar
AWAna Raquel Whitaker
Ana Raquel Whitaker
MMMarília Paiva Martins
Marília Paiva Martins
DJDaniel Campos Jesus
Daniel Campos Jesus
ASAndrei C Sposito
Andrei C Sposito

1 January 2026 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
EEEurico Joaquim Lutucuta Ernesto
Eurico Joaquim Lutucuta Ernesto
ANAna Claudia Cavalcante Nogueira
Ana Claudia Cavalcante Nogueira
LSLuis Gustavo Sedenho-Prado
Luis Gustavo Sedenho-Prado
LYLouise Buonalumi Tacito Yugar
Louise Buonalumi Tacito Yugar
MMMarília Paiva Martins
Marília Paiva Martins
ASAndrei C Sposito
Andrei C Sposito
Resumo Fundamento Os bloqueadores dos receptores da angiotensina II (BRAs) antagonizam o receptor AT1 e são anti-hipertensivos eficazes. Diferenças modestas na eficácia da redução da pressão arterial têm sido relatadas, refletindo variações na farmacocinética, na ligação ao receptor, na duração da ação e em potenciais efeitos pleiotrópicos. Entretanto, os dados sobre seus efeitos comparativos nos desfechos cardiovasculares em pacientes são escassos. Objetivo Avaliar os efeitos dos BRAs sobre eventos cardiovasculares adversos maiores (MACE), hospitalização por insuficiência cardíaca (HHF) e mortalidade por todas as causas em ensaios randomizados não delineados primariamente para avaliar insuficiência cardíaca (IC). Métodos As bases de dados MEDLINE/PubMed, Cochrane Central Register of Controlled Trials e ClinicalTrials.gov foram pesquisadas até maio de 2025. Foram incluídos ensaios clínicos randomizados publicados que relataram eventos cardiovasculares adversos maiores (MACE), HHF ou morte por todas as causas, envolvendo BRAs, com pelo menos 100 indivíduos por braço e acompanhamento ≥12 meses. Estudos focados principalmente em pacientes com IC preexistente foram excluídos. Taxas de incidência de HHF, MACE e morte por todas as causas. Foi realizada uma metanálise em rede de efeitos aleatórios, incluindo 27 ensaios clínicos randomizados e 702.584 pacientes-ano. Resultados O candesartana reduziu MACE em comparação ao placebo (OR 0,79; IC 95%, 0,63–0,97; SUCRA=0,85), apresentando a melhor classificação entre os BRAs, enquanto a telmisartana demonstrou uma redução menor, porém significativa (OR 0,90; IC 95%, 0,80–0,99; SUCRA=0,61). A análise baseou-se em dados em nível de estudo; as redes de tratamentos incluídas eram moderadamente esparsas, com comparações predominantemente indiretas entre os BRAs. Conclusão Esta metanálise em rede, realizada em pacientes sem IC basal, indica que a candesartana e a telmisartana reduzem MACE, sugerindo diferenças clinicamente relevantes entre os BRAs. Considerando a natureza predominantemente indireta de várias comparações, esses achados devem ser interpretados com cautela.

1 January 2026 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
EEEurico Joaquim Lutucuta Ernesto
Eurico Joaquim Lutucuta Ernesto
ANAna Claudia Cavalcante Nogueira
Ana Claudia Cavalcante Nogueira
LSLuis Gustavo Sedenho-Prado
Luis Gustavo Sedenho-Prado
LYLouise Buonalumi Tacito Yugar
Louise Buonalumi Tacito Yugar
MMMarília Paiva Martins
Marília Paiva Martins
ASAndrei C Sposito
Andrei C Sposito
Background Angiotensin II receptor blockers (ARBs) antagonize the AT1 receptor and are effective antihypertensives. Modest differences in blood pressure-lowering efficacy have been reported, reflecting variations in pharmacokinetics, receptor binding, duration of action, and potential pleiotropic effects. However, data on their comparative effects on cardiovascular outcomes in patients are scarce. Objective To assess the effects of ARBs on MACE, hospitalization for heart failure (HHF), and all-cause mortality in randomized trials not primarily designed to evaluate heart failure (HF). Methods MEDLINE/PubMed, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov databases were searched until May 2025. Published RCTs reporting major adverse cardiovascular events (MACE), HHF or all-cause death, involving ARBs, with at least 100 individuals per arm and ≥12 months of follow-up, were included. Studies focusing primarily on patients with existing HF were excluded. Incidence rates of HHF, MACE, and all-cause death. A random-effects network meta-analysis including 27 RCTs and 702,584 patient-years was performed. Results Candesartan reduced MACE versus placebo (OR 0.79; 95% CI, 0.63–0.97; SUCRA=0.85), ranking highest among ARBs, while telmisartan showed a smaller but significant reduction (OR 0.90; 95% CI, 0.80–0.99; SUCRA=0.61). The analysis relied on study-level data; included moderately sparse treatment networks with predominantly indirect comparisons between ARBs. Conclusion This network meta-analysis in patients without baseline HF indicates that candesartan and telmisartan reduce MACE, suggesting clinically meaningful differences among ARBs. Given the predominantly indirect nature of several comparisons, these findings should be interpreted cautiously.